Therapeutic options for chronic myeloid leukemia: Focus on imatinib (Glivec®, Gleevec™)

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 163-187

  Henkes, Martin ^a   van der Kuip, Heiko ^b,c   Aulitzky, Walter E ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

CML therapy; Imatinib; Novel kinase inhibitors; SCT

Indexed keywords

2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; AMINOTRANSFERASE; ANTIEMETIC AGENT; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BILIRUBIN; BOSUTINIB; BUSULFAN; CALCIUM; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; EVEROLIMUS; HYDROXYUREA; IMATINIB; LEVOTHYROXINE; LONAFARNIB; MAGNESIUM; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NILOTINIB; PARACETAMOL; PEGINTERFERON ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PREDNISONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN; UNINDEXED DRUG;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ALLOGENEIC STEM CELL TRANSPLANTATION; ANASARCA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASCITES; AUTOIMMUNE DISEASE; BEDTIME DOSAGE; BLAST CELL CRISIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE REMODELING; BRAIN EDEMA; CANCER REGRESSION; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOPENIA; DEPRESSION; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; ENCEPHALOCELE; ERYTHEMA MULTIFORME; EXENCEPHALY; FATIGUE; FETUS DISEASE; FLUID RETENTION; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; GRAPEFRUIT JUICE; HAIR DISEASE; HEADACHE; HEMATOPOIESIS; HUMAN; HYPERPARATHYROIDISM; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; IMMUNE DEFICIENCY; INFECTION; INFERTILITY; JOINT EFFUSION; LICHENOID ERUPTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG EDEMA; LUNG TOXICITY; MEMORY; METABOLIC DISORDER; MORTALITY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OLIGOSPERMIA; OSTEOLYSIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT MONITORING; PERICARDIAL EFFUSION; PERIORBITAL EDEMA; PIGMENT DISORDER; PLEURA EFFUSION; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; SKULL MALFORMATION; SPERMATOZOON MOTILITY; STEVENS JOHNSON SYNDROME; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SURVIVAL RATE; TERATOGENICITY; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; UMBILICAL HERNIA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 41549110244     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (260)

1. Al Sobhi E, Zahrani Z, Zevallos E, et al. 2007. Imatinib-induced immune hepatitis:case report and literature review. Hematology, 12:49-53.
2. Ali R, Ozkalemkas F, Ozkan A, et al. 2007. Tumour lysis syndrome with acute renal failure during imatinib therapy. Leuk Res, 31:573-4.
3. Ali R, Ozkalemkas F, Ozkocaman V, et al. 2004. Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy:a case report and review of the literature. Jpn J Clin Oncol, 34:215-7.
4. Aoki E, Kantarjian H, O,Brien SG, et al. 2006. High-dose imatinib provides better responses in patients with untreated early chronic phase CML [abstract]. Blood, 108:608a.
5. Atallah E, Kantrjian H, Cortes J. 2007a. Emerging safety issues with Imatinib and other Abl tyrosine kinase inhibitors. Clin Lymphoma and Myeloma, 3:105-12.
6. Atallah EL, Kantarjian H, O'Brien S, et al. 2007b. Use of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CP-CML) [abstract]. J Clin Oncol, 25:7006a.
7. Ault P, Kantarjian H, O'Brien S, et al, 2006. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol, 24:1204-8.
8. Azam M, Latek RR, Daley GQ. 2003. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell, 112:931-43.
9. Baccarani M, Martinelli G, Rosti G, et al. 2004. Imatinib and pegylated human recombinant interferon alpha2b in early chronic-phase chronic myeloid leukemia. Blood, 104:4245-51.
10. Baccarani M, Rosti G, de Vivo A, et al. 2002. A randomized study of interferon-alpha versus interferon-alpha and low-dose ara-binosyl cytosine in chronic myeloid leukemia. Blood, 99:1527-35.
11. Baccarani M, Russo D, Rosti G, et al. 2003. Interferon-alfa for chronic myeloid leukemia. Semin Hematol, 40:22-33.
12. Baccarani M, Saglio G, Goldman J, et al. 2006. Evolving concepts in the management of chronic myeloid leukemia:xecommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108:1809-20.
13. Barnes DJ, Melo JV. 2002. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol, 108:180-202.
14. Barnes DJ, Palaiologou D, Panousopoulou E, et al. 2005. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res, 65:8912-9.
15. Barthe C, Cony-Makhoul P, Melo JV, et al. 2001. Roots of clinical resistance to STI-571 cancer therapy. Science, 293:2163.
16. Bergeron A, Bergot E, Vilela G et al. 2002. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol, 20:4271-2.
17. Bergstrom DA, Clark JB, Xiao A, et al. 2006. MK-0457, a novel multikinase inhibitor, inhibits BCR-ABL activity inpatients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T3151 BCR-ABL Mutation [abstract]. Blood, 108:637a.
18. Berman E, Nicolaides M, Maki RG, et al. 2006. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med, 354:2006-13.
19. Beumer JH, Natale JJ, Lagattuta TF, et al. 2006. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. Pharmacotherapy, 26:903-7.
20. Bonifazi F, de Vivo A, Rosti G, et al. 2001. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood, 98:3074-81.
21. Bornhäuser M, Kröger N, Schwerdtfeger R, et al. 2006. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib:a retrospective multicentre study. Eur J Haematol, 76:9-17.
22. Borthakur G, Kantarjian H, Daley G, et al. 2006, Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer, 106:346-52.
23. Branford S, Cross NC, Hochhaus A, et al. 2006. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia, 20:1925-30.
24. Branford S, Rudzki Z, Parkinson I, et al. 2004. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood, 104:2926-32.
25. Branford S, Rudzki Z, Walsh S, et al. 2002. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukaemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99:3472-5.
26. + Chronic Myelogenous Leukemia patients responsive to treatment. J Clin Oncol, 22:4653-5.
27. Buchdunger E, Zimmermann J, Mett H, et al. 1996. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res, 56:100-4.
28. Burchert A, Wang Y, Cai D, et al. 2005. Compensatory PI3-kinase/Akt/ mTor activation regulates imatinib resistance development. Leukemia, 19:1774-82.
29. Burger H, van Tol H, Boersma AW, et al. 2004. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood, 104:2940-2.
30. Burgess MR, Skaggs BJ, Shah NP, et al. 2005. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci, 102:3395-400.
31. Buser CA, Furey B, Hoover R, et al. 2007. Contribution of the kinase cross-reactivity profile of MK-0457 to clinical activity [abstract]. J Clin Oncol, 25:7050a.
32. Carpenter PA, Snyder DS, Flowers MED, et al. 2007. Prophylactic administration of imatimb after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood, 109:2791-3.
33. Carter TA, Wodicka LM, Shah NP, et al. 2005. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl A cad Sci, 102:11011-6.
34. Cervantes F, Hernandez-Boluda JC, Steegmann JL, et al. 2003. Imatinib mesylate therapy of chronic phase chronic mycloid leukemia resistant or intolerant to interferon:results and prognostic factors for response and progression-free survival in 150 patients. Haematologica, 88:1117-22.
35. Cheetham GM, Charlton PA, Golec JM, et al. 2007. Structural basis for potent inhibition of the Aurora kinases and a T3151 multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett. Jan 18, (Epub ahead of print).
36. Choudhary DR, Mishra P, Kumar R, et al. 2006. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol, 17:178-9.
37. Chronic Myeloid Leukemia Trialists' Collaborative Group. 1997. Interferon alfa versus chemotherapy for chronic myeloid leukemia:a meta-analysis of seven randomized trials. J Natl Cancer Inst, 89:1616-20.
38. Cohen MH, Williams G, Johnson JR, et al. 2002. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res, 8:93 5-42.
39. Corbin AS, La Rosee P, Stoffregen EP, et al. 2003. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood, 101:4611-4.
40. Cortes J, Giles F, O'Brien S, et al. 2003. Result of highdose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood, 102:83-6.
41. Cortes J, O'Brien S, Verstovsek S, et al. 2004. Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib [abstract]. Blood, 104:1009.
42. Cortes J, Rousselot P, Kim DW, et al. 2007. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109:3207-13.
43. Cortes J. 2004. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am, 18:569-84.
44. +) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatimb [abstract]. Blood, 108:168a.
45. Cowan-Jacob SW, Guez V, Fendrich G, et al. 2004. Imatinib (STI571) resistance in chronic myelogenous leukemia:molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem, 4:285-99.
46. +) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib [abstract]. J Clin Oncol, 25:7046a.
47. Cross TJ, Bagot C, Portmann B, et al. 2006:Imatinib mesylate as a cause of acute liver failure. Am J Hematol, 81:189-92.
48. Dai Y, Rahmani M, Corey SJ, et al. 2004. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem, 279:34227-39.
49. DeAngelo DJ, Hochberg EP, Alyea EP, et al. 2004. Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation:durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res, 10:5065-71.
50. de Groot JWB, Links TP and van der Graaf WTA. 2006. Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol, 17:1719-20.
51. de Groot J, Zonnenberg B, Plukker W, et al. 2005. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther, 78:433-8.
52. Deininger MW, Goldman JM, Lydon N, et al. 1997. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90:3691-8.
53. Deininger MW, O'Brien SG, Ford JM, et al. 2003. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol, 21:1637-47.
54. Deininger MW, Schleuning M, Greinix H, et al. 2006. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica, 91:452-9.
55. Deininger MW. 2005. Chronic myeloid leukemia. Management of early stage disease. Hematology, 174-82.
56. Dengler J, von Bubnoff N, Decker T, et al. 2005. Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. Leukemia, 19:1835-8.
57. Dewar AL, Farrugia AN, Condina MR, et al. 2006. Imatinib as a potential antiresorptive therapy for bone disease. Blood, 107:4334-7.
58. Dhalluin-Venier V, Besson C, Dimet S, et al. 2006. Imatinib mesylate-induced acute hepatitis with autoimmune features. Eur J Gastroenterol Hepatol, 18:1235-7.
59. Donato NJ, Wu JY, Stapley J, et al. 2003. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood, 101:690-8.
60. Druker BJ, Guilhot F, O'Brien SG, et al. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355:2408-17.
61. Druker BJ, Talpaz M, Resta DJ, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344:1031-7.
62. Druker BJ, Tamura S, Buchdunger E, et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 2:561-6.
63. Ebnoether M, Stentoft J, Ford J, et al. 2002. Cerebral oedema as a possible complication of treatment with imatinib. Lancet, 359:1751-2.
64. Faderl S, Talpaz M, Estrov Z, et al. 1999a. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med, 131:207-19.
65. Faderl S, Talpaz M, Estrov Z, et al. 1999b. The biology of chronic myeloid leukemia. N Engl J Med, 341:164-72.
66. Ferrero D, Pogliani EM, Rege-Cambrin G. 2006. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica, 91:35-7.
67. Gambacorti C, Talpaz M, Sawyers C, et al. 2005. Five year follow-up results of a phase II trial in patients with late chronic phase chronic myeloid leukemia treated with Imatinib who are refractory/intolerant of Interferon-α [abstract]. Blood, 106:1089a.
68. Gambacorti-Passerini C, Brummendorf T, Kantarjian H, et al. 2007. Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib [abstract]. J Clin Oncol, 25:7006a.
69. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. 2003. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res, 9:625-32.
70. Gambacorti-Passerini C, Barni R, le Coutre P, et al. 2000. Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the ab1 inhibitor STI571. J Natl Cancer Inst, 92:1641-50.
71. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. 1997. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis, 23:380-94.
72. Gardembas M, Rousselot P, Tulliez M, et al. 2003. Results of a prospective phase 2 study combining Imatinib Mesylate and Cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood, 102:4298-305.
73. Gardner ER, Burger H, van Schaik RH, et al. 2006. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther, 90: 192-201.
74. Giles F, le Coutre P, Bhalla K, et al. 2007a. A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib [abstract]. J Clin Oncol, 25:7038a.
75. Giles F, Cortes J, Bergstrom DA, et al. 2006b. MK-0457, a novel Aurora Kinase and BCR-ABL inhibitor, is active against BCR-ABL T315I mutant Chronic Myelogenous Leukemia (CML) [abstract]. Blood, 108:163a.
76. Giles F, le Coutre P, Bhalla K, et al. 2006a. A phase II study of Nilotinib, a novel tyrosine kinase inhibitor administered to patients with Imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed Dasatinib therapy [abstract). Blood, 108:2170a.
77. Giles FJ, Cortes J, Jones D, et al. 2007b. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood, 109:500-2.
78. Giralt S, Arora M, Goldman JM et al. 2007. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Brit J Haematol, 137:461-7.
79. Gorre ME, Mohammed M, Ellwood K, et al. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293:876-80.
80. Gratwohl A, Schmid O, Baldomero H, et al. 2004. Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey. Bone Marrow Transplant, 34:855-75.
81. Gratwohl A, Brand R, Apperley J, et al. 2006. Allogeneic hematopoietic SCT for chronic myeloid leukemia in Europe 2006:transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica, 91:513-21.
82. Gratwohl A, Hermans J, Goldman JM, et al. 1998. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet, 352:1087-92.
83. Grey A, O'Sullivan S, Reid IR, et al. 2006. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med, 355:2494-5.
84. Griswold IJ, MacPartlin M, Bumm T, et al. 2006. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol, 26:6082-93.
85. Gschwind HP, Pfaar U, Waldmeier F, et al. 2005. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos, 33:1503-12.
86. Guglielmi C, Arcese W, Dazzi F, et al. 2002. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia:prognostic relevance of the initial cell dose. Blood, 100:397-405.
87. Guilhot F, Apperley J, Kim DW, et al. 2007. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, Jan 30, (Epub ahead of print).
88. Guilhot F, Chastang C, Michallet M, et al. 1997. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med, 337:223-9.
89. Gumireddy K, Baker SJ, Cosenza SC, et al. 2005. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA, 102:1992-7.
90. Hamberg F, de Jong FA, Boonstra JG, et al. 2006. Non-islet-cell tumor induced hypoglycemia in patients with advanced Gastrointestinal Stromal Tumor possibly worsened by Imatinib. J Clin Oncol, 24:e30-e31.
91. Hardan I, Amariglio N, Trakhtenbrot L, et al. 2006. Towards stopping Imatinib therapy under the umbrella of Interferone:Alpha-Interferone improves molecular response in CML patients with Imatinib induced complete cytogenetic remission:An early observation from a study of pegylated Interferone in the setup of minimal residual disease. Blood, 108:4788a.
92. Harrington EA, Bebbington D, Moore J, et al. 2004. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med, 10:262-7.
93. Hasford. J, Pfirrmann. M, Hehlmann R, et al. 1998. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst, 90:850-8.
94. Hehlmann R, Berger U, Hochhaus A. 2005. Chronic myeloid leukemia:a model for oncology. Ann Hematol, 84:487-97.
95. Hehlmann R, Berger U, Pfirrmann M, et al. 2007. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood, Feb 22, (Epub ahead of print).
96. Hehlmann R, Heimpel H, Hasford J, et al. 1993. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia:prolongation of survival by hydroxyurea. The German CML Study Group. Blood, 82:398-407.
97. Hehlmann R, Heimpel H, Hasford J, et al. 1994. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood, 84:4064-77.
98. Hochhaus A, Kantarjian HM, Baccarani M, et al. 2007. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 109:2303-9.
99. Hochhaus A, Kim DW, Rousselot P, et al. 2006. Dasatinib (SPRYCEL®) 50 mg or 70 mg BID versus 100 mg or 140 mg QD in patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant or intolerant to Imatinib: Results ofthe CA180-034 Study [abstract]. Blood, 108:166a.
100. Hochhaus A, Kreil S, Corbin AS, et al. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 16:2190-6.
101. Hochhaus A, Lin F, Reiter A, et al. 1995. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol, 9:126-31.
102. Hochhaus A, Lin F, Reiter A, et al. 1996. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood, 87:1549-55.
103. Hochhaus A, Reiter A, Saussele S, et al. 2000. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia:low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood, 95:62-6.
104. + acute lymphoblastic leukemia. Blood, 102:659-61.
105. Hoover RR, Mahon FX, Melo JV, et al. 2002. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood, 100:1068-71.
106. Houghton PJ, Germain GS, Harwood FC, et al. 2004. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res, 64:2333-7.
107. Hsiao LT, Chung HM, Lin JT, et al. 2002. Stevens-Johnson syndrome after treatment with STI571: A case report. Br J Haematol, 117:620-2.
108. Hu Y, Liu Y, Pelletier S, et al. 2004. Requirement of Sre kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet, 36:453-61.
109. Hughes T, Branford S, Reynolds J, et al. 2004. Higher dose Imatinib (600 mg/day) with selective intensification in newly diagnosed CML patients in chronic phase:cytogenetic response rates at 12 months are superior to IRIS [abstract]. Blood, 104:1001a.
110. Hughes T, Deininger M, Hochhaus A, et al. 2006. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108:28-37.
111. Hughes T. 2006. ABL Kinase inhibitor therapy for CML:baseline assessments and response monitoring. Hematology:211-17.
112. Hughes TP, Branford S, Reynolds J, et al. 2005. Maintenance of Imatinib dose intensity in the first six months of therapy for newly diagnosed patients with CML is predictive of molecular response, independent of the ability to increase dose at a later point [abstract]. Blood, 106:164a.
113. Hughes TP, Kaeda J, Branford S, et al. 2003. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med, 349:1423-32.
114. Illmer T, Schaich M, Platzbecker U, et al. 2004. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia, 18:401-8.
115. Inokuchi K. 2006. Chronic myelogenous leukemia:from molecular biology to clinical aspects and novel targeted therapies. J Nippon Med Sch, 73:178-92.
116. Issa JP, Gharibyan V, Cortes J, et al. 2005. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol, 23:3948-56.
117. Issaad C, Ahmed M, Novault S, et al. 2000. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7. Leukemia, 14:662-70.
118. Isshiki I, Yamaguchi K, Okamoto S. 2004. Interstitial pneumonitis during imatinib therapy. Br J Haematol, 125:420.
119. Jayson GC, Parker GJ, Mullamitha S, et al. 2005. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol, 23:973-81.
120. Jabbour E, le Coutre P, Baccarani M, et al. 2007. Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) [abstract]. J Clin Oncol, 25:7039a.
121. Joensuu H, Reichardt P. 2006. Correspondence: Imatinib and Altered Bone and Mineral Metabolism. N Engl J Med, 355:628.
122. Jonuleit T, Peschel C, Schwab R, et al. 1998. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. Br J Haematol, 100:295-303.
123. Jonuleit T, van der Kuip H, Miething C, et al. 2000. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood, 96:1933-9.
124. Jorgensen HG, Allan EK, Graham SM, et al. 2005. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 19:1184-91.
125. Kantarjian H, Cortes J, O'Brien S, et al. 2004a. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon alpha. Blood, 104:1979-88.
126. Kantarjian H, Giles F, Wunderle L, et al. 2006a. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med, 354:2542-51.
127. Kantarjian H, O'Brien S, Talpaz M, et al. 2007b. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer, 109:1556-60.
128. Kantarjian H, Pasquini R, Hamerschlak N, et al. 2007a. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood, Feb 22, (Epub ahead of print).
129. Kantarjian H, Sawyers C, Hochhaus A, et al. 2002a. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 346:645-52.
130. Kantarjian H, Talpaz M, O'Brien S, et al. 2002b. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res, 8:2177-87.
131. Kantarjian H, Talpaz M, O'Brien S, et al. 2003a. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 101:473-5.
132. Kantarjian H, Talpaz M, O'Brien S, et al. 2004b. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood, 103:2873-8.
133. Kantarjian HM, Gattermann N, Hochhaus A, et al. 2006b. A phase II study of Nilotinib a novel tyrosine kinase Inhibitor administered to Imatinib-resisbtant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) [abstract]. Blood, 108:2169a.
134. Kantarjian HM, O'Brien S, Cortes JE, et al. 2002c. Imatinib mesylate therapy for relapse after allogeneic SCT for chronic myelogenous leukemia. Blood, 100:1590-5.
135. Kantarjian HM, O'Brien S, Cortes J, et al. 2003b. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer, 98:522-8.
136. Kantarjian HM, O'Brien S, Smith TL. 1999. Treatment of philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol, 17:284-92.
137. Keeshan K, Mills KI, Cotter TG, et al. 2001. McKenna SL. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia, 15:1823-33.
138. Kerkela R, Grazette L, Yacobi R, et al. 2006. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med, 12:908-16.
139. Kim DW, Chung YJ, Lee S, et al. 2004. Pretransplant Imatinib can improve the outcome of non myeloablative SCT without increasing the mortality in Philadelphia-chromosome positive chronic myeloid leukemia. Leukemia, 18:1907-9.
140. Kluin-Nelemans HC, Buck G, le Cessie S, et al. 2004. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood, 103:4408-15.
141. Koleske AJ, Gifford AM, Scott ML, et al. 1998. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron, 21:1259-72.
142. Kuhr T, Burgstaller S, Apfelbeck U, et al. 2003. A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). Leuk Res, 27:405-11.
143. Kuwano Y, Asahina A, Watanabe R, et al. 2006. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia. Int J Dermatol, 45:1249-51.
144. Larson RA, Druker BJ, Guilhot F, et al. 2006. Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with Imatinib - an analysis of IRIS study data. Blood, 108:429a.
145. le Coutre P, Bhalla K, Giles G, et al. 2007. A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukenia (CML) in chronic phase (CP) [abstract]. J Clin Oncol, 25:7007a.
146. + chronic myeloid leukemia during the first 13 weeks of therapy with ST1571. Blood Cells Mol Dis, 28:75-85.
147. le Coutre P, Tassi E, Varella-Garcia M, et al. 2000. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood, 95:1758-66.
148. Lee SJ. 2000. Chronic myelogenous leukaemia. Br J Haematol, 111:993-1009.
149. Lin NU, Sarantopoulos S, Stone JR, et al. 2003. Fatal hepatic necrosis following imatinib mesylate therapy. Blood, 102:3455-6.
150. Lindahl P, Johansson BR, Leveen P, et al. 1997. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science, 277:242-5.
151. Lionberger JM, Wilson MB, Smithgall TE. 2000. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem, 275:18581-5.
152. Ly C, Arechiga AF, Melo JV, et al. 2003. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res, 63:5716-22.
153. Ma CX, Hobday TJ, Jett JR. 2003. Imatinib mesylate-induced interstitial pneumonits. Mayo Clin Proc, 78:1578-9.
154. Mahon FX, Deininger MW, Schultheis B, et al. 2000. Chabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571:diverse mechanisms of resistance. Blood, 96:1070-9.
155. Marin D, Marktel S, Foot N, et al. 2003. Granulocyte colony-stimulation factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica, 88:227-9.
156. Martin JM, Jorda E, Monteagudo C, et al. 2006. Follicular acneiform eruption induced by imatinib. J Eur Acad Dermatol Venereol, 20:1368-70.
157. Martinelli G, Soverini S, Iacobucci I, et al. 2007. MK-0457:a light at the end of the tunnel ? Blood, 109:396-7.
158. Matthews N, Visintin C, Hartzoulakis B, et al. 2006. Aurora A and B kinases as targets for cancer:will they be selective for tumors? Expert Rev Anticancer Ther, 6:109-20.
159. Medeiros BC, Lipton JH. 2006. Chlordiazepoxide for imatinib-induced muscular cramps. Eur J Haematol, 77:538.
160. Michallet M, Maloisel F, Delain M, et al. 2004. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia:a phase III study. Leukemia, 18:309-15.
161. Mohi MG, Boulton C, Gu TL, et al. 2004. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA, 101:3130-5.
162. Muller MC, Lahaye T, Hochhaus A. 2002. Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells. Dtsch Med Wochenschr, 127:2205-7.
163. Nagar B, Bornmann WG, Pellicena P, et al. 2002. Crystal structures of
164. Nakanishi T, Shiozawa K, Hassel BA, et al. 2006. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells:BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood, 108:678-84.
165. Nguyen TT, Mohrbacher AF, Tsai YC, et al. 2000. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia:biological implications. Blood, 95:2990-2.
166. Nowell PC, Hungerford DA. 1960. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst, 25:85-109.
167. O'Hare T, Eide CE, Deininger MWN. 2007. Bcr-Abl Kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia. Blood, May 11, (Epub ahead of print).
168. O'Hare T, Walters DK, Stoffregen EP, et al. 2005. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res, 65:4500-5.
169. O'Brien S, Kantarjian H, Talpaz M. 1996. Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. Leuk Lymphoma, 23:247-52.
170. O'Brien SG, Guilhot F, Larson RA, et al. 2003. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 348:994-1004.
171. Oehler VG, Gooley T, Snyder DS, et al. 2007. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood, 109:1782-89.
172. Oetzel C, Jonuleit T, Gotz A, et al. 2000. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res, 6:1958-68.
173. Ohnishi K, Sakai F, Kudoh S, et al. 2006. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia, 20:1162-4.
174. Ohyashiki K, Kuriyama Y, Nakajima A, et al. 2002. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia, 16:2160-1.
175. Oki Y, Kantarjian HM, Gharibyan V, et al. 2007. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer, 109:899-906.
176. Olavarria E, Ottmann OG, Deininger M, et al. 2003. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia, 17:1707-12.
177. Ottmann O, Kantarjian HM, Larson R, et al. 2006. A phase II study of Nilotinib, a novel tyrosine kinase inhibitor administered to Imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) [abstract]. Blood, 108: 1862a.
178. Owen S, Hatfield A, Letvak L. 2006. Correspondence:Imatinib and Altered Bone and Mineral Metabolism. N Engl J Med, 355:627.
179. Ozvegy-Laczka C, Hegedus T, Varady G, et al. 2004. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol, 65:1485-95.
180. Passweg JR, Walker I, Sobocinski KA, et al. 2004. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia receiving allogeneic haematopoietic stem cell transplants. Br J Haematol, 125:613-20.
181. Pavithran K, Thomas M. 2005. Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose. Indian J Dermatol Venereol Leprol, 71:288-9.
182. Peng B, Hayes M, Resta D, et al. 2004. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol, 22:935-42.
183. Peng B, Lloyd P, Schran H. 2005. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet, 44:879-94.
184. Peters DG, Hoover RR, Gerlach MJ, et al. 2001. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood, 97:1404-12.
185. Petzer AL, Eaves CJ, Lansdorp PM, et al. 1996. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood, 88:2162-71.
186. + ALL). Blood, Apr 3, (Epub ahead of print).
187. Picard S, Titier K, Etienne G, et al. 2007. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 109:3496-9.
188. Pilot PR, Sablinska K, Owen S, et al. 2006. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia, 20:148.
189. Popescu LM, Vidulescu C, Curici A, et al. 2006. Imatinib inhibits spontaneous rhythmic contractions of human uterus and intestine. Eur J Pharmacol, 546:177-81.
190. Prabhash K, Sastry PS, Biswas G, et al. 2005. Pregnancy outcome of two patients treated with imatinib. Ann Oncol, 16:1983-4.
191. Ptasznik A, Nakata Y, Kalota A, et al. 2004. Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med, 10:1187-9.
192. Pye S, Cortes J, Rosti G, et al. 2006. Imatinib and Pregnancy [abstract]. Blood, 108:431a.
193. Radich JP, Gooley T, Bensinger W, et al. 2003. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood, 102:31-5.
194. Ray A, Cowan-Jacob SW, Manley P, et al. 2007. Identification of Bcr-Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood, Feb 15, (Epub ahead of print).
195. Robert C, Soria JC, Spatz A, et al. 2005. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncology, 6:491-500.
196. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. 2002. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, 100:1014-8.
197. Rosado MF, Donna E, Ahn YS. 2003. Challenging problems in advanced malignancy:case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol, 21:3171-3.
198. Rosti G, Martinelli G, Bassi S, et al. 2004. Molecular response to imatinib in late chronic phase chronic myeloid leukemia. Blood, 103:2284-90.
199. Rowley JD. 1973. Letter:A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243:290-3.
200. Roy L, Guilhot J, Krahnke T, et al. 2006. Survival advantage from imatinib compared with the combination interferon alpha plus cytarabine in chronic-phase chronic myelogenous leukemia:historical comparison between two phase 3 trials. Blood, 108:1478-84.
201. Roy L, Guilhot J, Martineau G, et al. 2005. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia, 19:1689-92.
202. Rule SA, O'Brien SG, Crossman LC. 2002. Managing cutaneous reactions to imatinib therapy. Blood, 100:3434-5.
203. Sacchi S, Kantarjian H, O'Brien S, et al. 1995. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol, 13:2401-7.
204. Samanta AK, Lin H, Sun T, et al. 2006. Janus kinase 2:a critical target in chronic myelogenous leukemia. Cancer Res, 66:6468-72.
205. Sanchez-Gonzalez B, Pascual-Ramirez JC, Fernandez-Abellan P, et al. 2003. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. Blood, 101:2446.
206. Sawyers CL, Callahan W, Witte ON. 1992. Dominant negative MYC blocks transformation by ABL oncogenes. Cell, 70:901-10.
207. Sawyers CL, Hochhaus A, Feldman E, et al. 2002. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis:results of a phase 2 study. Blood, 99:3530-9.
208. Sawyers CL. 1999. Chronic myeloid leukemia. N Engl J Med, 340:1330-40.
209. Scheinfeld N. 2006. Imatinib mesylate and dermatopathy part 2:a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol, 5:228-31.
210. Schellings MW, Lowenberg B, Pinto YM, et al. 2007. Another Look at Imatinib Mesylate. New Engl J of Med, 356:1183.
211. Schindler T, Bornmann W, Pellicena P, et al. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 289:1938-42.
212. Schmidli H, Peng B, Riviere GJ, et al. 2005. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia:results of a phase III study. Br J Clin Pharmacol, 60:35-44.
213. Schwartzberg PL, Stall AM, Hardin JD, et al. 1991. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell, 65:1165-75.
214. Seymour JF, Grigg A, Reynolds J, et al. 2006. Two year data from a prospective safety study analyzing the consequences of Imatinib Mesylate inhibition of sensitive kinases other than bcr-abl in patients with previously untreated chronic phase CML [abstract]. Blood, 108:2147a.
215. Shah NP, Nicoll JM, Nagar B, et al. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2:117-25.
216. Shah NP, Tran C, Lee FY, et al. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305:399-401.
217. Shah NP, Skaggs B, Branford S, et al. 2006a. Sequential kinase inhibitor iherapy in CML patients can select for cells harboring compound BCR-ABL kinase domain mutations with increased oncogenic potency: Rationale for early combination therapy of ABL kinase inhibitors [abstract]. Blood, 108:751a.
218. Shah NP, Skaggs B, Branford S, et al. 2006b. The most common Dasatinib-resistant BCR-ABL kinase domain mutations in patients with Chronic Myeloid Leukemia are sensitive to VX-680:Rationale for early combination kinase inhibitor therapy [abstract]. Blood, 108:2175a.
219. Shimoni A, Kröger N, Zander AR, et al. 2003. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic SCT and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia, 17:290-7.
220. Silver RT, Peterson BL, Szatrowski TP, et al. 2003. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine:results from CALGB study 9013. Leuk Lymphoma, 44:39-48.
221. Silver RT, Talpaz M, Sawyers CL, et al. 2004. Four years of follow-up of 1027 patients with late chronic phase, accelerated phase, or blast crisis chronic myeloid leukemia treated with Imatinib in three large phase II trials [abstract]. Blood, 104:23a.
222. Silver RT, Woolf SH, Hehlmann R, et al. 1999. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood, 94:1517-36.
223. Skaggs BJ, Gorre ME, Ryvkin A, et al. 2006. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA, 103:19466-71.
224. Sokal JE, Cox EB, Baccarani M, et al. 1984. Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood, 63:789-99.
225. Soverini S, Tasco G, Grafone T, et al. 2007. Binding mode of the tyrosine kinase inhibitor bosutinib (SKI-606) to Abl kinase [abstract]. J Clin Oncol, 25:7049a.
226. Soverini S, Colarossi S, Gnani A, et al. 2006. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients:by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res, 12:7374-9.
227. Stylian A, Fennely ET, Butler JP, et al. 2006. Allogeneic transplant outcomes in Imatinib-refractory chronic myeloid leukaemia (CML) are similar to transplant outcomes in Imatinib-responsive/Imatinib-naive CML and appear to be predicted by the EBMT risk score [abstract]. Blood, 108:3155a.
228. Suppiah R, Kalaycio M. 2006. Successful outcome of pregnancy in a patient with chronic myelogenous leukemia exposed to imatinib during the first trimester. Leuk Lymphoma, 47:1149-50.
229. Talpaz M, Kantarjian H, Kurzrock R, et al. 1991. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med, 114:532-8.
230. Talpaz M, Kantarjian HM, McCredie KB, et al. 1986. Hematologic remission and cytogenetic improvement induced by recombinant human interferon-α in chronic myelogenous leukemia. N Engl J Med, 314:1065-9.
231. Talpaz M, McCredie KB, Mavligit GM, et al. 1983. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood, 62:689-92.
232. Talpaz M, Shah NP, Kantadian H, et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 354:2531-41.
233. Talpaz M, Silver RT, Druker BJ, et al. 2002. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia:results of a phase 2 study. Blood, 99:1928-37.
234. The Benelux CML Study Group. 1998. Randomized Study on Hydroxyurea. alone versus Hydroxyurea combined with low-dose Interferon-2b for Chronic Myeloid Leukemia. Blood, 91:2713-21.
235. Thomas J, Wang L, Clark RE, et al. 2004. Active transport of imatinib into and out of cells implications for drug resistance. Blood, 104:3739-45.
236. Tokarski JS, Newitt JA, Chang CY, et al. 2006. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res, 66:5790-7.
237. van der Kuip H, Moehring A, Wohlbold L, et al. 2004. Imatinib mesylate (ST1571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines. Leuk Res, 28:405-8.
238. van der Kuip H, Wohlbold L, Oetzel C, et al. 2005. Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases. Am J Pharmacogenomics, 5:101-12.
239. Vardiman JW, Harris NL, Brunning RD. 2002. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100:2292-302.
240. Vidal D, Puig L, Sureda A, et al. 2002. ST1571-Induced Stevens-Johnson syndrome. Br J Haematol, 119:274-5.
241. von BubnoffN, Schneller F, Peschel C, et al. 2002. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to ST1571: a prospective study. Lancet, 359:487-91.
242. von BubnoffN, Veach DR, van der Kuip H, et al. 2005. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood, 105:1652-9.
243. Wang Y, Cai D, Brendel C, et al. 2007, Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+progenitors via JAK-2/ STAT-5 pathway activation. Blood, 109:2147-55.
244. Weisberg E, Griffin JD. 2001. Mechanisms of resistance imatinib (ST1571) in preclinical models and in leukemia patients. Drug Resist Updat, 4:22-8.
245. Weisberg E, Manley P, Mestan J, et al. 2006. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer, 94:1765-9.
246. Weisberg E, Manley PW, Breitenstein W, et al. 2005. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7:129-41.
247. Weisberg E, Manley P, Cowan-Jacob SW, et al. 2007. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature Reviews Cancer, 7:345-56.
248. Weisdorf DJ, Anasetti C, Antin JH, et al. 2002. Allogeneic bone marrow transplantation for chronic myelogenous leukemia:comparative analysis of unrelated versus matched sibling donor transplantation. Blood, 99:1971-77.
249. Weisser M, Schleuning M, Haferlach C, et al. 2007, Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma, 48:195-201.
250. Wetzler M, Kantarjian H, Kurzrock R, et al. 1995. Interferon-alpha therapy for chronic myelogenous leukemia. Am J Med, 99:402-11.
251. Wilkinson GR. 2005. Drug metabolism and variability among patients in drug response. N Engl J Med, 352:2211-21.
252. Willis SG, Lange T, Demehri S, et al. 2005. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients:correlation with clonal cytogenetic evolution but not response to therapy. Blood, 106:2128-37.
253. Wohlbold L, van der Kuip H, Miething C, et al. 2003. Inhibition of berabl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood, 102:2236-9.
254. Xie S, Lin H, Sun T, et al. 2002. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene, 21:7137-46.
255. Xie S, Wang Y, Liu J, et al. 2001. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene, 20:6188-95.
256. + leukemia cells in the central nervous system, and cyclosporine A augments its in vivo action. Blood, 109:306-14.
257. Young MA, Shah NP, Chao LH, et al. 2006. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res, 66:1007-14.
258. Zaucha JM, Prejzner W, Giebel S, et al. 2005. Imatinib therapy prior to myeloablative allogeneic SCT. Bone Marrow Transplant, 36:417-24.
259. Zion M, Ben-Yehuda D, Avraham A, et al. 1994. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA, 91:10722-6.
260. Zonder JA, Pemberton P, Brandt H, et al. 2003. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res, 9:2092-7.